# US 2024/0189434 A1 · Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189434 A1
- Document ID: US20240189434A1
- Status: Published application
- Kind: A1
- Application number: 18/281,700
- Filed: 2022-03-11
- Published: 2024-06-13
- Earliest claimed: 2021-03-12
- Assignees: Pepgen Corporation
- Applicants: PepGen Inc.
- Inventors: Caroline GODFREY; Sonia BRACEGIRDLE; Ashling HOLLAND; Smita GUNNOO
- Web page: https://patentgrep.com/patent/US20240189434A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/54: the modifying agent being an organic compound
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N 2310/11: Antisense
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/3513: Protein; Peptide
- C12N 2320/35: based on a specific dosage / administration regimen
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods of treating a subject having myotonic dystrophy type 1 (DM1). The methods include administering a therapeutic regimen including a plurality of doses of a conjugate spaced at a time interval of at least 1 month, where the conjugate includes an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide including a hydrophobic domain flanked by two cationic domains, each of the cationic domains including one of RBRRBRR (SEQ ID NO: 1), RBRBR (SEQ ID NO: 2), RBRR (SEQ ID NO: 3), RBRRBR (SEQ ID NO: 4), RRBRBR (SEQ ID NO: 5), RBRRB (SEQ ID NO: 6), BRBR (SEQ ID NO: 7), RBHBH (SEQ ID NO: 8), HBHBR (SEQ ID NO: 9), RBRHBHR (SEQ ID NO: 10), RBRBBHR (SEQ ID NO: 11), RBRRBH (SEQ ID NO: 12), HBRRBR (SEQ ID NO: 13), HBHBH (SEQ ID NO: 14), BHBH (SEQ ID NO: 15), BRBSB (SEQ ID NO: 16), BRB[Hyp]B (SEQ ID NO: 17), R[Hyp]H[Hyp]HB (SEQ ID NO: 18), and R[Hyp]RR[Hyp]R (SEQ ID NO: 19), and the hydrophobic domain including one of YQFLI (SEQ ID NO: 20), FQILY (SEQ ID NO: 21), ILFQY (SEQ ID NO: 22), FQIY (SEQ ID NO: 23), VWVW, WWPWW (SEQ ID NO: 24), WPWW (SEQ ID NO: 25), and VWVPW (SEQ ID NO: 26); and the oligonucleotide including a total of 12 to 40 contiguous nucleobases, where at least 9 contiguous nucleobases are complementary to a CUG repeat sequence.

## Claims

### Claim 1

A method of treating a subject having myotonic dystrophy type 1 (DM1), the method comprising administering a therapeutic regimen comprising a plurality of doses of a conjugate spaced at a time interval of at least 1 month, wherein the conjugate comprises an oligonucleotide and a peptide covalently bonded or linked via a linker to the oligonucleotide, the peptide comprising a hydrophobic domain flanked by two cationic domains, each of the cationic domains comprising one of RBRRBRR (SEQ ID NO: 1), RBRBR (SEQ ID NO: 2), RBRR (SEQ ID NO: 3), RBRRBR (SEQ ID NO: 4), RRBRBR (SEQ ID NO: 5), RBRRB (SEQ ID NO: 6), BRBR (SEQ ID NO: 7), RBHBH (SEQ ID NO: 8), HBHBR (SEQ ID NO: 9), RBRHBHR (SEQ ID NO: 10), RBRBBHR (SEQ ID NO: 11), RBRRBH (SEQ ID NO: 12), HBRRBR (SEQ ID NO: 13), HBHBH (SEQ ID NO: 14), BHBH (SEQ ID NO: 15), BRBSB (SEQ ID NO: 16), BRB[Hyp]B (SEQ ID NO: 17), R[Hyp]H[Hyp]HB (SEQ ID NO: 18), and R[Hyp]RR[Hyp]R (SEQ ID NO: 19), and the hydrophobic domain comprising one of YQFLI (SEQ ID NO: 20), FQILY (SEQ ID NO: 21), ILFQY (SEQ ID NO: 22), FQIY (SEQ ID NO: 23), WWW, WWPWW (SEQ ID NO: 24), WPWW (SEQ ID NO: 25), and WWPW (SEQ ID NO: 26); and
the oligonucleotide comprising a total of 12 to 40 contiguous nucleobases, wherein at least 9 contiguous nucleobases are complementary to a CUG repeat sequence.

### Claim 2 (depends on 1)

The method of claim 1, wherein the time interval is 1 to 6 months.

### Claim 3 (depends on 1)

The method of claim 1, wherein the time interval is 2 to 6 months.

### Claim 4 (depends on 1)

The method of claim 1, wherein the time interval is 3 to 6 months.

### Claim 5 (depends on 1)

The method of claim 1, wherein the time interval is 4 to 6 months.

### Claim 6 (depends on 1)

The method of claim 1, wherein the time interval is 5 to 6 months.

### Claim 7 (depends on 1)

The method of claim 1, wherein the time interval is 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, the therapeutic regimen further comprising a treatment initiation regimen comprising administering the conjugate three or four times at an initiation interval of 2 weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein the oligonucleotide is 5′-[CAG]n-3′, wherein n is an integer from 5 to 8.

### Claim 10 (depends on 9)

The method of claim 9, wherein the oligonucleotide is 5′-[CAG]5-3′.

### Claim 11 (depends on 9)

The method of claim 9, wherein the oligonucleotide is 5′-[CAG]6-3′.

### Claim 12 (depends on 9)

The method of claim 9, wherein the oligonucleotide is 5′-[CAG]7-3′.

### Claim 13 (depends on 9)

The method of claim 9, wherein the oligonucleotide is 5′-[CAG]8-3′.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the oligonucleotide is 5′-[AGC]n-3′, wherein n is an integer from 5 to 8.

### Claim 15 (depends on 14)

The method of claim 14, wherein the oligonucleotide is 5′-[AGC]5-3′.

### Claim 16 (depends on 14)

The method of claim 14, wherein the oligonucleotide is 5′-[AGC]6-3′.

### Claim 17 (depends on 14)

The method of claim 14, wherein the oligonucleotide is 5′-[AGC]7-3′.

### Claim 18 (depends on 14)

The method of claim 14, wherein the oligonucleotide is 5′-[AGC]8-3′.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the oligonucleotide is 5′-[GCA]n-3′, wherein n is an integer from 5 to 8.

### Claim 20 (depends on 19)

The method of claim 19, wherein the oligonucleotide is 5′-[GCA]5-3′.

### Claim 21 (depends on 19)

The method of claim 19, wherein the oligonucleotide is 5′-[GCA]6-3′.

### Claim 22 (depends on 19)

The method of claim 19, wherein the oligonucleotide is 5′-[GCA]7-3′.

### Claim 23 (depends on 19)

The method of claim 19, wherein the oligonucleotide is 5′-[GCA]8-3′.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the peptide has the following amino acid sequence RBRRBRFQILYBRBR (SEQ ID NO: 35).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the peptide has the following amino acid sequence RBRRBRRFQILYRBHBH (SEQ ID NO: 37).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the peptide has the following amino acid sequence RBRRBRFQILYRBHBH (SEQ ID NO: 44).

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the peptide is bonded to the rest of the conjugate through its N-terminus.

### Claim 28 (depends on 27)

The method of claim 27, wherein the C-terminus of the peptide is —CONH2.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the peptide is bonded to the rest of the conjugate through its C-terminus.

### Claim 30 (depends on 29)

The method of claim 29, wherein the peptide is acylated at its N-terminus.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:
[peptide]—[linker]—[oligonucleotide]

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:
[peptide]—[linker]—[peptide]—[linker]—[oligonucleotide]

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein each linker is independently of formula (I):
T1—(CR1R2)n—T2. (I)
wherein
T1 is a divalent group for attachment to the peptide and is selected from the group consisting of —NH- and carbonyl;
T2 is a divalent group for attachment to an oligonucleotide and is selected from the group consisting of —NH- and carbonyl;
n is 1, 2 or 3;
each R1 is independently -Y1-X1-Z1,
wherein
Y1 is absent or —(CRA1RA2)m-, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each independently hydrogen, OH, or (1-2C)alkyl;
X1 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORA3)—, —N(RA3)—, —N(RA3)—C(O)—, —N(RA3)—C(O)O—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(NRA3)N(RA3)—, —SO—, —S—, —SO2—, —S(O)2N(RA3)-, or —N(RA3)SO2-, wherein each RA3 is independently selected from hydrogen and methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl,
wherein each (1 -6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, and heteroaryl is optionally substituted with one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRA4RA5, and (1-4C)alkoxy, wherein RA4 and RA5 are each independently selected from the group consisting of hydrogen and (1-4C)alkyl; and
each R2 is independently -Y2-X2-Z2, wherein
Y2 is absent or a group of the formula —[CRB1RB2]m- in which m is an integer selected from 1, 2, 3 or 4, and RB1 and RB2 are each independently selected from hydrogen, OH or (1-2C)alkyl;
X2 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORB3)—, —N(RB3)—, —N(RB3)—C(O)—, —N(RB3)—C(O)O—, —C(O)—N(RB3)—, —N(RB3)C(O)N(RB3)—, —N(RB3)C(NRB3)N(RB3)—, —SO—, —S— —SO2—, —S(O)2N(RB3)—, or —N(RB3)SO2-, wherein each RB3 is independently selected from hydrogen or methyl; and
Z2 is selected from hydrogen, (1 -6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl, wherein each (1 -6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl or heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRB4RB5, and (1-4C)alkoxy, wherein RB4 and RB5 are each independently hydrogen or (1-2C)alkyl; with the proviso that; when n=1 and T1 and T2 are different to one another, then R1 and R2 are not both H; when n=1, T1 and T2 are different to one another and one of R1 and R2 is H then the other of R1 and R2 is not methyl; or when n=2 and each occurrence of R1 and R2 is H, then T1 and T2 are both —C(O)- or are both —NH-.

### Claim 35 (depends on 34)

The method of claim 34, wherein T2 is —C(O)-.

### Claim 36 (depends on 34)

The method of claim 34, wherein each R1 is independently -Y1-X1-Z1, wherein:
Y1 is absent or —(CRA1RA2)m-, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each hydrogen or (1-2C)alkyl;
X1 is absent, —O—, —C(O)—, —C(O)O—, —N(RA3)—, —N(RA3)—C(O)—, —C(O)—N(R3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(NRA3)N(RA3)- or —S-, wherein each RA3 is independently hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, or heteroaryl, wherein each (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, and heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, oxo, halo, cyano, nitro, hydroxy, carboxy, NRA4RA5, and (1-4C)alkoxy, wherein RM and RA5 are each independently hydrogen or (1-2C)alkyl.

### Claim 37 (depends on 34)

The method of claim 34, wherein each R1 is independently -Y1-X1-Z1, wherein:
Y1 is absent or —(CRA1RA2)m-, wherein m is 1, 2, 3, or 4, and RA1 and R″ are each independently hydrogen or (1-2C)alkyl;
X1 is absent, —O—, —C(O)—, —C(O)O—, —N(RA3)—, —N(RA3)—C(O)—, —C(O)—N(RA3)—, —N(RA3)C(O)N(RA3)—, —N(RA3)C(NRA3)N(RA3)-, or —S-, wherein each RA3 is independently hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, or heteroaryl, wherein each (1-6C)alkyl, aryl, (3-6C)cycloalkyl, and heteroaryl is optionally substituted by one or more substituent groups selected from the group consisting of (1-4C) alkyl, halo, and hydroxy.

### Claim 38 (depends on 34)

The method of claim 34, wherein each R1 is independently -Y1-X1-Z1, wherein:
Y1 is absent or a group of the formula —(CRA1RA2)m-, wherein m is 1, 2, 3 or 4, and RA1 and RA2 are each independently hydrogen or (1-2C)alkyl;
X1 is absent, —C(O)—, —C(O)O—, —N(RA3)—C(O)—, —C(O)—N(RA3)-, wherein each RA3 is hydrogen or methyl; and
Z1 is a further oligonucleotide or is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, or heteroaryl, wherein each (1-6C)alkyl, aryl, (3-6C)cycloalkyl, and heteroaryl is optionally substituted by one or more (e.g., 1, 2, 3, 4, or 5) substituent groups selected from the group consisting of (1-4C) alkyl, halo, and hydroxy.

### Claim 39 (depends on 34)

The method of claim 34, wherein each R1 is independently -Y1-X1-Z1, wherein:
Y1 is absent, —(CH2)-, or —(CH2CH2)-;
X1 is absent, —N(RA3)—C(O)—, —C(O)—N(RA3)-, wherein each RA3 is independently hydrogen or methyl; and
Z1 is hydrogen or (1-2C)alkyl.

### Claim 40 (depends on 34)

The method of claim 34, wherein each R2 is independently -Y2-Z2,
wherein Y2 is absent or —(CRB1RB2)m-, wherein m is 1, 2, 3 or 4, and RB1 and RB2 are each independently hydrogen or (1-2C)alkyl; and
Z2 is hydrogen or (1-6C)alkyl.

### Claim 41 (depends on 34)

The method of claim 34, wherein each R2 is hydrogen.

### Claim 42 (depends on 34)

The method of claim 34, wherein n is 2 or 3.

### Claim 43 (depends on 34)

The method of claim 34, wherein n is 1.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is an amino acid residue selected from the group consisting of glutamic acid, succinic acid, and gamma-aminobutyric acid residues.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is of the following structure:

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is of the following structure:

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is of the following structure:

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is of the following structure:

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the linker is of the following structure:

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the oligonucleotide is bonded to the linker or the peptide at its 3′ terminus.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is of the following structure:

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the oligonucleotide is a morpholino.

### Claim 63

The method of 62, wherein all morpholino internucleoside linkages in the morpholino are —P(O)(NMe2)O-.

### Claim 64 (depends on 63)

The method of claim 63, wherein the oligonucleotide comprises the following group as its 5′ terminus:

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the oligonucleotide comprises the following group as its 5′ terminus:

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the conjugate is administered parenterally.

### Claim 67 (depends on 66)

The method of claim 66, wherein the conjugate is administered intravenously.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein each dose within the plurality of doses comprises 5-60 mg/kg of the conjugate.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein each dose within the plurality of doses comprises 40 mg/kg to 60 mg/kg, 30 mg/kg to 50 mg/kg, 30 mg/kg to 40 mg/kg, 40 mg/kg to 50 mg/kg, 50 mg/kg to 60 mg/kg, 35 mg/kg to 45 mg/kg, 45 mg/kg to 55 mg/kg, 35 mg/kg to 55 mg/kg, 30 mg/kg to 45 mg/kg, 35 mg/kg to 50 mg/kg, 40 mg/kg to 55 mg/kg, 45 mg/kg to 60 mg/kg, 1 mg/kg to 30 mg/kg, 1 mg/kg to 20 mg/kg, 5 mg/kg to 25 mg/kg, 10 mg/kg to 30 mg/kg, 1 mg/kg to 15 mg/kg, 5 mg/kg to 20 mg/kg, 10 mg/kg to 25 mg/kg, 15 mg/kg to 30 mg/kg, 1 mg/kg to 10 mg/kg, 5 mg/kg to 15 mg/kg, 10 mg/kg to 20 mg/kg, 15 mg/kg to 25 mg/kg, 20 mg/kg to 30 mg/kg, 1 mg/kg to 25 mg/kg, 4 mg/kg to 20 mg/kg, 6 mg/kg to 15 mg/kg, or 8 mg/kg to 10 mg/kg of the conjugate.

### Claim 70 (depends on 69)

The method of claim 69, wherein each dose within the plurality of doses comprises 1 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 8 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, or 60 mg/kg of the conjugate.
